Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: In Vitro Activity against SARS-CoV-2 and Potential Mechanisms
Ana C. Puhl, Ethan J. Fritch, Thomas R. Lane, et al.
ACS Omega (2021) Vol. 6, Iss. 11, pp. 7454-7468
Open Access | Times Cited: 65

Showing 1-25 of 65 citing articles:

Construction and applications of SARS-CoV-2 pseudoviruses: a mini review
Minghai Chen, Xian‐En Zhang
International Journal of Biological Sciences (2021) Vol. 17, Iss. 6, pp. 1574-1580
Open Access | Times Cited: 91
Recent advances in developing small-molecule inhibitors against SARS-CoV-2
Rong Xiang, Zhengsen Yu, Yang Wang, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 12, Iss. 4, pp. 1591-1623
Open Access | Times Cited: 68
Experimental Models of COVID-19
Luis A. Caldera-Crespo, Michael J. Paidas, Sabita Roy, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 11
Open Access | Times Cited: 38
Recent advances in drug repurposing using machine learning
Fabio Urbina, Ana C. Puhl, Sean Ekins
Current Opinion in Chemical Biology (2021) Vol. 65, pp. 74-84
Open Access | Times Cited: 45
Machine Learning Models Identify Inhibitors of SARS-CoV-2
Victor O. Gawriljuk, Phyo Phyo Kyaw Zin, Ana C. Puhl, et al.
Journal of Chemical Information and Modeling (2021) Vol. 61, Iss. 9, pp. 4224-4235
Open Access | Times Cited: 43
Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal
Kunal Nepali, Ram Lal Sharma, Sachin Sharma, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 27
Studying molecular interactions via capillary electrophoresis and microscale thermophoresis: A review
Mufarreh Asmari, Lenka Michalcová, Adel Ehab Ibrahim, et al.
Electrophoresis (2023) Vol. 44, Iss. 13-14, pp. 1114-1142
Open Access | Times Cited: 16
Novel antiviral approaches for Marburg: a promising therapeutics in the pipeline
Shriyansh Srivastava, Sachin Kumar, Sumel Ashique, et al.
Frontiers in Microbiology (2024) Vol. 15
Open Access | Times Cited: 4
Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites
Siennah R. Miller, Meghan E. McGrath, Kimberley M. Zorn, et al.
Molecular Pharmacology (2021) Vol. 100, Iss. 6, pp. 548-557
Open Access | Times Cited: 34
Mechanisms of Lung Injury Induced by SARS-CoV-2 Infection
Samsara Upadhya, Jalees Rehman, Asrar B. Malik, et al.
Physiology (2021) Vol. 37, Iss. 2, pp. 88-100
Open Access | Times Cited: 34
Atazanavir Is a Competitive Inhibitor of SARS-CoV-2 Mpro, Impairing Variants Replication In Vitro and In Vivo
Otávio Augusto Chaves, Carolina Q. Sacramento, André C. Ferreira, et al.
Pharmaceuticals (2021) Vol. 15, Iss. 1, pp. 21-21
Open Access | Times Cited: 34
Pyronaridine Protects against SARS-CoV-2 Infection in Mouse
Ana C. Puhl, Giovanni Freitas Gomes, Samara Damasceno, et al.
ACS Infectious Diseases (2022) Vol. 8, Iss. 6, pp. 1147-1160
Open Access | Times Cited: 22
Discovery of PLpro and Mpro Inhibitors for SARS-CoV-2
Ana C. Puhl, André S. Godoy, G.D. Noske, et al.
ACS Omega (2023) Vol. 8, Iss. 25, pp. 22603-22612
Open Access | Times Cited: 11
Repurposing of SARS-CoV-2 compounds against Marburg Virus using MD simulation, mm/GBSA, PCA analysis, and free energy landscape
Sanjay Kumar, Rajni Dubey, Richa Mishra, et al.
Journal of Biomolecular Structure and Dynamics (2024), pp. 1-20
Closed Access | Times Cited: 3
Friend or Foe? Implication of the autophagy-lysosome pathway in SARS-CoV-2 infection and COVID-19
Weifeng He, Yuan Gao, Jing Zhou, et al.
International Journal of Biological Sciences (2022) Vol. 18, Iss. 12, pp. 4690-4703
Open Access | Times Cited: 20
Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization
J. J. Patten, Patrick T. Keiser, Deisy Morselli-Gysi, et al.
iScience (2022) Vol. 25, Iss. 9, pp. 104925-104925
Open Access | Times Cited: 17
Human iPS cell-derived sensory neurons can be infected by SARS-CoV-2
Anthony Flamier, Punam Bisht, Alexsia Richards, et al.
iScience (2023) Vol. 26, Iss. 9, pp. 107690-107690
Open Access | Times Cited: 9
A Drug Repurposing Approach for Antimalarials Interfering with SARS-CoV-2 Spike Protein Receptor Binding Domain (RBD) and Human Angiotensin-Converting Enzyme 2 (ACE2)
Paolo Coghi, Li Yang, Jerome P. L. Ng, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 10, pp. 954-954
Open Access | Times Cited: 23
Synthesis and Antiviral Properties against SARS-CoV-2 of Epoxybenzooxocino[4,3-b]Pyridine Derivatives
Alena L. Stalinskaya, Nadezhda V. Martynenko, Zarina Shulgau, et al.
Molecules (2022) Vol. 27, Iss. 12, pp. 3701-3701
Open Access | Times Cited: 15
An Overview on Anti-COVID-19 Drug Achievements and Challenges Ahead
Mehdi Valipour, Hamid Irannejad, Hossein Keyvani
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 9, pp. 1248-1265
Open Access | Times Cited: 8
In silico identification of chikungunya virus replication inhibitor validated using biochemical and cell‐based approaches
Meenakshi Chaudhary, Akash Kumar, Kiran Bala Sharma, et al.
FEBS Journal (2024) Vol. 291, Iss. 12, pp. 2656-2673
Closed Access | Times Cited: 2
Mapping knowledge landscapes and emerging trends of Marburg virus: A text-mining study
Yuanjun Lyu, Wanqing Li, Qiang Guo, et al.
Heliyon (2024) Vol. 10, Iss. 8, pp. e29691-e29691
Open Access | Times Cited: 2
Vandetanib Blocks the Cytokine Storm in SARS-CoV-2-Infected Mice
Ana C. Puhl, Giovanni Freitas Gomes, Samara Damasceno, et al.
ACS Omega (2022) Vol. 7, Iss. 36, pp. 31935-31944
Open Access | Times Cited: 13
Targeting cytokine storm as the potential anti-viral therapy: Implications in regulating SARS-CoV-2 pathogenicity
Subhasish Maity, Ayantika Santra, Ananda Vardhan Hebbani, et al.
Gene (2023) Vol. 881, pp. 147612-147612
Closed Access | Times Cited: 7
Discovery of potential anti-SARS-CoV-2 drugs based on large-scale screening in vitro and effect evaluation in vivo
Haoran Peng, Cui‐Ling Ding, Liangliang Jiang, et al.
Science China Life Sciences (2021) Vol. 65, Iss. 6, pp. 1181-1197
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top